Victor Forge
Adeno-associated viruses (AAVs) are a group of non-pathogenic, naturally replication-deficient parvoviruses that have shown promise as a tool for gene delivery in skeletal muscle. AAV-based therapies have demonstrated encouraging results for the treatment of various genetic disorders, including muscular dystrophy. However, challenges remain in achieving efficient transduction across the entire muscular system and avoiding toxicity in non-target tissues. The transduction efficiency of AAVs varies between serotypes, and understanding the myofiber-type transduction preference is crucial for optimizing AAV-mediated gene therapy. Recent studies have identified novel myotropic AAVs, such as MyoAAVs and AAVMYOs, which exhibit enhanced muscle transduction efficiency and liver de-targeting effects. The development of muscle-specific promoters and miRNA-based de-targeting strategies are also being explored to improve the specificity and safety of AAV-based treatments.
Explore related products
$17.54 $23.99
What You'll Learn
- AAV-based therapies are promising for treating muscular dystrophy
- MyoAAVs and AAVMYOs are novel myotropic AAVs with enhanced muscle transduction efficiency
- AAVs are an efficient tool for gene delivery in skeletal muscle
- Tissue-specific promoter or miRNA-based de-targeting strategy can reduce transgene immunity
- AAV tropism at the myofiber type level can improve transduction efficacy and specificity
AAV-based therapies are promising for treating muscular dystrophy
Adeno-associated viruses (AAVs) are a diverse group of non-pathogenic, naturally replication-deficient parvoviruses. AAV-based gene therapy is a promising treatment for muscular dystrophy (MD), a group of progressive genetic diseases affecting the musculature. MD is characterized by inflammatory infiltrates, necrosis, and connective tissue and fat replacement of the affected muscles.
AAV-based therapies are being developed to replace mutant disease-causing genes, knock down dominant disease-causing genes using antisense oligonucleotides or inhibitory RNAs, and deliver gene-editing tools such as CRISPR-Cas9. Clinical trials with microdystrophins are showing promising results, although challenges such as limited transgene size and the threat of an anti-dystrophin immune response remain.
The natural diversity of AAV serotypes and recent technologies to engineer the AAV capsid have provided a wide range of rAAV vectors with distinct biological profiles. These vectors can efficiently deliver genes to muscle tissues, and some serotypes, such as rAAV9, can achieve highly efficient widespread gene transfer after localized intramuscular injection.
Recently, novel myotropic AAVs named MyoAAVs and AAVMYOs have been discovered, demonstrating enhanced muscle transduction efficiency and liver de-targeting effects. MyoAAV2A has been highlighted for its ability to transduce leg muscles, while AAVMYO is promising for diaphragm transduction. In addition, specific AAV serotypes are more potent for transducing skeletal muscles, including the diaphragm, and de-targeting the heart or liver.
In summary, AAV-based therapies are a promising approach for treating muscular dystrophy. The ability of AAVs to deliver genes to muscle tissues efficiently, coupled with the development of specific serotypes and myotropic AAVs, makes them a valuable tool for future clinical trials and treatments for muscular dystrophy.
Muscle Calcification: Understanding the Process and Causes
You may want to see also
Explore related products
MyoAAVs and AAVMYOs are novel myotropic AAVs with enhanced muscle transduction efficiency
Adeno-associated virus (AAV)-based gene therapy is a promising strategy for treating muscle diseases. However, it faces challenges such as low transduction efficiency across the entire muscular system and toxicity resulting from off-target tissue effects. This is where novel myotropic AAVs, MyoAAVs and AAVMYOs, come into play. They have been discovered using a directed evolution approach and have shown enhanced muscle transduction efficiency and liver de-targeting effects.
MyoAAVs and AAVMYOs are two newly discovered myotropic AAVs that have been individually demonstrated to have enhanced muscle transduction efficiency. They were discovered using a directed evolution approach. MyoAAVs and AAVMYOs share the "RGD" motif (Arginine, Glycine, Aspartic Acid), which is known to interact with the integrin family, some of which are expressed on the surface of muscle cells. This makes them promising tools for gene therapy in muscle diseases.
A comparative analysis of these myotropic AAVs in wild-type mice revealed differences in transduction efficiency between AAV9, AAVMYO, MyoAAV2A, and MyoAAV4A, depending on factors like age, dose, and genetic background. The study also showed that specific AAV serotypes were more effective in transducing skeletal muscles, including the diaphragm, and de-targeting the heart or liver.
MyoAAV2A, for example, was highlighted for its superior leg muscle transduction capabilities, while AAVMYO stood out for diaphragm transduction and liver de-targeting. These findings indicate that MyoAAVs could be a promising therapeutic tool for future clinical trials, although their efficiency and specificity in humans are yet to be established.
Muscle Evolution: Bone Transformation Unveiled
You may want to see also
Explore related products
AAVs are an efficient tool for gene delivery in skeletal muscle
Adeno-associated viruses (AAVs) are a diverse collection of non-pathogenic, naturally replication-deficient parvoviruses. They are composed of a linear single-stranded (ss) DNA genome and a small non-enveloped capsid. AAVs are an efficient tool for gene delivery in skeletal muscle due to their natural tropism to muscle cells, long-term persistent transgene expression, multiple serotypes, and minimal immune response.
AAV vectors have been shown to efficiently transduce skeletal muscle, resulting in long-term, stable protein expression. This makes them well-suited for muscle-directed gene therapy, particularly for the treatment of muscular dystrophy. In addition, muscle can be used as a therapeutic platform for AAV vectors to express non-muscle secretory/regulatory pathway proteins for diseases such as diabetes, atherosclerosis, hemophilia, and cancer.
AAV-based therapies have shown promising results in the treatment of various genetic disorders, including muscular dystrophy. The tropism of each AAV serotype has been extensively studied using systemic delivery routes, but few studies have compared their transduction efficiency through direct intramuscular injection. However, in some muscular dystrophies, where only a few muscles are primarily affected, local intramuscular injection may be the most appropriate route.
Recombinant AAV (rAAV) vectors have been used as therapeutic tools for Duchenne muscular dystrophy (DMD) and have shown promising results in animal studies and clinical trials. However, there are still challenges to overcome, such as the large amount of vector needed to transduce the entire muscular system and the potential for toxicity in other organs, especially the liver. Nonetheless, AAV-based vectors hold great promise for the future of gene therapy in skeletal muscle due to their ability to efficiently deliver genes to muscle tissues.
The Etymology of Muscle Names: Unraveling the Linguistic Origins
You may want to see also
Explore related products
Tissue-specific promoter or miRNA-based de-targeting strategy can reduce transgene immunity
Adeno-associated viruses (AAVs) are a group of non-pathogenic, naturally replication-deficient parvoviruses that have been used as vectors for gene delivery to muscle tissue. While AAVs have shown promise for safe and effective in vivo gene delivery, there are challenges associated with their use, such as the need for a large amount of vector to transduce the entire muscular system and toxicity caused in other organs, especially the liver.
To overcome these challenges, researchers have developed strategies to improve the tissue specificity of AAVs. One approach is to use tissue-specific promoters that restrict AAV vector-mediated transgene expression to the desired tissue. For example, in the case of cardiac-specific gene delivery, a variety of cardiac-specific promoters have been investigated to restrict transgene expression to the heart upon intravenous injection. Similarly, in the context of muscle-specific gene delivery, tissue-specific promoters can be used to restrict transgene expression to muscle tissue, reducing transgene immunity.
Another strategy to improve tissue specificity is the use of microRNA-based de-targeting. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by binding to specific sequences in the mRNA. By incorporating binding sites for miRNAs into the 3' end of the transgene expression cassette, it is possible to fine-tune vector expression and turn it on or off in a tissue-specific manner. This approach has been successfully employed to reduce the immune response against the transgene and increase the safety of live attenuated virus vaccines.
In addition to tissue-specific promoters and miRNA-based de-targeting, other targeting strategies have been explored to improve the tissue specificity of AAVs. These include switching the virus serotype, capsid engineering via directed evolution, and the creation of vectors with chimeric or mosaic structures. By combining these strategies, researchers aim to maximize the specificity of AAV vector expression and reduce off-target effects, thereby minimizing potential adverse events and improving the safety and efficacy of gene therapy.
Understanding Muscle Diseases: Causes, Effects, and Treatments
You may want to see also
Explore related products
AAV tropism at the myofiber type level can improve transduction efficacy and specificity
Adeno-associated viruses (AAVs) are a diverse collection of non-pathogenic, naturally replication-deficient parvoviruses. They are among the most effective gene delivery systems, with 12 AAV serotypes and over 100 variants currently identified.
AAV-derived transgene expression is sustainable, consistent over time, and safe in preclinical applications. However, transduction efficiency in skeletal muscles varies between AAV serotypes, with the underlying factors poorly understood.
In addition, specific AAV serotypes are more potent for transducing skeletal muscles, including the diaphragm, and/or for de-targeting the heart or liver. For instance, MyoAAV2A has been identified for superior leg muscle transduction, while AAVMYO is better for diaphragm transduction and liver de-targeting.
Furthermore, the directed evolution of AAV capsid variants enables potent muscle-directed gene delivery across species. By using this strategy, researchers have identified a class of RGD motif-containing capsids that transduce muscle with superior efficiency and selectivity after intravenous injection in mice and non-human primates.
Overall, adjusting AAV serotypes for specific muscle conditions can improve transduction efficacy in clinical applications.
Understanding Muscle Weakness: Causes and Effects
You may want to see also
Frequently asked questions
Adeno-associated viruses (AAVs) are a diverse group of non-pathogenic, naturally replication-deficient parvoviruses. They are used as vectors for gene therapy.
While AAVs are not inherently muscle-specific, they can be designed to be muscle-specific. The tropism of each AAV serotype is different, and some serotypes, such as AAV6 and AAV9, have been found to be more suitable for muscle-specific applications.
Some challenges include achieving efficient transduction across the entire muscular system, toxicity resulting from off-target effects, and pre-existing immunity against AAVs.
